You can buy or sell Trevena and other stocks, options, ETFs, and crypto commission-free!
Trevena, Inc. Common Stock, also called Trevena, is a biopharmaceutical company, which focuses on the development and commercialization of innovative treatment options that target and treat diseases affecting the central nervous system, or CNS. Read More The company product pipeline consists of Olinvo, TRV250, and TRV734. Trevena was founded by Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.
52 Week High
52 Week Low
Yahoo FinanceMay 10
Trevena: 1Q Earnings Snapshot
CHESTERBROOK, Pa. (AP) _ Trevena Inc. (TRVN) on Friday reported a loss of $5.2 million in its first quarter. On a per-share basis, the Chesterbrook, Pennsylvania-based company said it had a loss of 6 cents. The company's shares closed at $1.55. A year ago, they were trading at $1.98. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TRVN at https://www.zacks.com/ap/TRVN...
Simply Wall StApr 26
Trevena, Inc. (NASDAQ:TRVN): Will The Growth Last?
The latest earnings announcement Trevena, Inc. (NASDAQ:TRVN) released in December 2018 showed company earnings became less negative compared to the previous year’s level as a result of recent tailwinds Investors may find it useful to understand how market analysts perceive Trevena’s earnings growth trajectory over the next couple of years and whether the future looks brighter. I will be looking at earnings excluding extraordinary items to exclude one-off activities to get a better understanding of the under...
-$0.08 per share
-$0.06 per share